Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.

Eyal, Nir; Gerhard, Tobias; Strom, Brian L

Eyal, Nir; Gerhard, Tobias; Strom, Brian L.

Eyal N; Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA, Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ, USA; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Gerhard T; Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, NJ, USA, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Strom BL; Rutgers Biomedical and Health Sciences, Newark, NJ, USA. Electronic address: bstrom@rbhs.rutgers.edu.

Vaccine ; 39(26): 3455-3458, 2021 06 11.

Article in English | MEDLINE | ID: covidwho-1386703

Subject(s)

COVID-19; Viral Vaccines; COVID-19 Vaccines; Humans; Prior Authorization; SARS-CoV-2

Keywords

Antibody dependent enhancement; Assessment, Risk benefit; Coronavirus; Ethics; Pharmacoepidemiology; Randomized clinical trials; Toxicity; Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.VACCINE.2021.04.056

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google